UCSF researchers are pioneering a groundbreaking clinical trial investigating whether targeting multiple Alzheimer's proteins simultaneously proves more effective than single-agent therapies. This innovative approach aims to intervene during early disease stages, before cognitive decline becomes severe. By combining treatments that address different pathological mechanisms, scientists hope to achieve better disease modification outcomes and potentially transform prevention strategies for at-risk populations.

Summary auto-generated by AI from the original publisher's content. Editorial standards.